Cerus Corporation (CERS) vs. Its Peers Critical Review
Cerus Corporation (NASDAQ: CERS) is one of 20 public companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Cerus Corporation to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Insider & Institutional Ownership
58.2% of Cerus Corporation shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Cerus Corporation shares are owned by insiders. Comparatively, 9.6% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for Cerus Corporation and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cerus Corporation Competitors||109||723||1018||10||2.50|
Cerus Corporation presently has a consensus price target of $7.00, suggesting a potential upside of 94.44%. As a group, “Medical Devices & Implants” companies have a potential upside of 38.30%. Given Cerus Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe Cerus Corporation is more favorable than its competitors.
This table compares Cerus Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cerus Corporation Competitors||-101.83%||-92.48%||-30.31%|
Earnings & Valuation
This table compares Cerus Corporation and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cerus Corporation||$39.28 million||-$62.90 million||-6.10|
|Cerus Corporation Competitors||$1.67 billion||$207.58 million||49.36|
Cerus Corporation’s competitors have higher revenue and earnings than Cerus Corporation. Cerus Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Cerus Corporation has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Cerus Corporation’s competitors have a beta of 0.36, indicating that their average stock price is 64% less volatile than the S&P 500.
Cerus Corporation competitors beat Cerus Corporation on 7 of the 12 factors compared.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.